- AstraZeneca and Merck said they had a received a positive opinion from EU regulators on a treatment for breast cancer.

The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the use of Lynparza tablets as monotherapy.

The treatment was more specifically for patients with germline BRCA1/2-mutations, who had human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.

'Despite progress in treating patients with advanced breast cancer, there remains a significant unmet need for new treatment options,' executive vice-president oncology Dave Fredrickson said.

'If approved, Lynparza will provide these patients with both a targeted and oral chemotherapy-free option.'

At 3:11pm: [LON:AZN] AstraZeneca PLC share price was +48.5p at 6187.5p

Story provided by